WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Percy Carter Biography and Net Worth

Insider of Blueprint Medicines

Percy brings more than 20 years of global leadership in pharmaceutical companies and industry experience. Prior to joining Blueprint Medicines, he served as Chief Scientific Officer at FibroGen, Inc. He previously served as Global Head of Discovery Sciences at Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson, where he led more than 700 employees comprising several key research and discovery functions, and drove the synthetic discovery strategy in collaboration with partners across various therapeutic areas. From August 2001 to May 2019, Percy held roles of increasing responsibility in drug discovery, covering all therapeutic areas, drug platforms and stages of discovery at Bristol-Myers Squibb (BMS), including serving as Senior Vice President and Head of Discovery. Prior to his experience at BMS, he was Senior Research Scientist in Chemical and Physical Sciences at DuPont Pharmaceuticals, until it was acquired by BMS in 2001. Percy is an inventor or co-inventor on more than 28 U.S. patents, and has authored or co-authored numerous peer-reviewed publications. He received an A.B. in Chemistry from Dartmouth College and a Ph.D. in Organic Chemistry from Harvard University. In addition, he received an MBA from Massachusetts Institute of Technology.

What is Percy H. Carter's net worth?: The estimated net worth of Percy H. Carter is at least $3.78 million as of June 5th, 2024. Dr. Carter owns 41,895 shares of Blueprint Medicines stock worth more than $3,776,415 as of December 21st. This net worth estimate does not reflect any other assets that Dr. Carter may own. Additionally, Dr. Carter receives a salary of $761,150.00 as Insider at Blueprint Medicines. Learn More about Percy H. Carter's net worth.
How old is Percy H. Carter?: Dr. Carter is currently 53 years old. There are 8 older executives and no younger executives at Blueprint Medicines. The oldest executive at Blueprint Medicines is Dr. Christopher K. Murray Ph.D., Senior VP of Technical Operations and Chief Technical Operations & Quality Officer, who is 60 years old. Learn More on Percy H. Carter's age.
What is Percy H. Carter's salary?: As the Insider of Blueprint Medicines Co., Dr. Carter earns $761,150.00 per year. There are 4 executives that earn more than Dr. Carter. The highest earning executive at Blueprint Medicines is Ms. Kathryn Haviland, President, CEO & Director, who commands a salary of $1,170,000.00 per year. Learn More on Percy H. Carter's salary.
How do I contact Percy H. Carter?: The corporate mailing address for Dr. Carter and other Blueprint Medicines executives is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. Blueprint Medicines can also be reached via phone at (617) 374-7580 and via email at [email protected]. Learn More on Percy H. Carter's contact information.
Has Percy H. Carter been buying or selling shares of Blueprint Medicines?: Percy H. Carter has not been actively trading shares of Blueprint Medicines during the last ninety days. Most recently, Percy H. Carter sold 4,000 shares of the business's stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $105.13, for a transaction totalling $420,520.00. Following the completion of the sale, the insider now directly owns 41,895 shares of the company's stock, valued at $4,404,421.35. Learn More on Percy H. Carter's trading history.
Who are Blueprint Medicines' active insiders?: Blueprint Medicines' insider roster includes Jeffrey Albers (CEO), Percy Carter (Insider), George Demetri (Director), Debra Durso-Bumpus (Insider), Mark Goldberg (Director), Kate Haviland (President, CEO & Director), L. Hewes (Insider), Ariel Hurley (Insider), Michael Landsittel (CFO), Philina Lee (Insider), Nicholas Lydon (Director), Tracey Mccain (EVP), Christopher Murray (Insider), Fouad Namouni (Insider), Christina Rossi (Insider), and Charles Rowland, Jr. (Director). Learn More on Blueprint Medicines' active insiders.
Are insiders buying or selling shares of Blueprint Medicines?: In the last twelve months, insiders at the biotechnology company sold shares 29 times. They sold a total of 329,167 shares worth more than $31,791,633.21. The most recent insider tranaction occured on December, 19th when Director Jeffrey W Albers sold 15,000 shares worth more than $1,346,550.00. Insiders at Blueprint Medicines own 4.2% of the company. Learn More about insider trades at Blueprint Medicines.
Information on this page was last updated on 12/19/2024.

Percy H. Carter Insider Trading History at Blueprint Medicines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/5/2024	Sell	4,000	$105.13	$420,520.00	41,895
6/5/2023	Sell	2,307	$52.06	$120,102.42	38,117
6/6/2022	Sell	1,908	$59.76	$114,022.08	28,685

Percy H. Carter Buying and Selling Activity at Blueprint Medicines

Blueprint Medicines Company Overview

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $90.14

$87.99

$90.99

50 Day Range

MA: $92.48

$82.47

$101.39

2 Week Range

Now: $90.14

$72.24

$121.90

Volume

1,267,436 shs

Average Volume

690,807 shs

Market Capitalization

$5.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Percy Carter Biography and Net Worth

What is Percy H. Carter's net worth?

How old is Percy H. Carter?

What is Percy H. Carter's salary?

How do I contact Percy H. Carter?

Has Percy H. Carter been buying or selling shares of Blueprint Medicines?

Who are Blueprint Medicines' active insiders?

Are insiders buying or selling shares of Blueprint Medicines?